In Israel, cushing's Syndrome is managed by endocrinologists. Cushing's syndrome is the constellation of physical and metabolic changes that result from chronic exposure to excess glucocorticoids, most often from prescribed corticosteroid medication and less commonly from endogenous overproduction of cortisol. Iatrogenic Cushing's is common — anyone on supraphysiologic prednisone, dexamethasone, or potent inhaled or topical steroids for more than a few weeks can develop the syndrome — while endogenous Cushing's is rare, with an incidence of 0.7-2.4 cases per million per year.
Cushing's syndrome (ICD-10: E24) is a clinical disorder caused by chronic exposure to excess glucocorticoid. Aetiologically it is divided into exogenous (iatrogenic) Cushing's, from administration of glucocorticoid medication, and endogenous Cushing's, from unregulated production of cortisol by the adrenal cortex. Endogenous Cushing's is further divided by ACTH dependence: ACTH-dependent forms (around 80%) include Cushing's disease (a pituitary corticotroph adenoma releasing ACTH, around 70% of endogenous cases) and ectopic ACTH syndrome (most often from small-cell lung carcinoma, bronchial or thymic carcinoid, medullary thyroid carcinoma, or pancreatic neuroendocrine tumor); ACTH-independent forms (around 20%) include unilateral cortisol-secreting adrenal adenoma, adrenal carcinoma, primary bilateral macronodular adrenal hyperplasia, and primary pigmented nodular adrenal disease. Cushing's disease is the name given specifically to the pituitary form, originally described by Harvey Cushing in 1932; Cushing's syndrome is the broader clinical phenotype regardless of cause.
The key symptoms of Cushing's Syndrome are: Progressive central obesity with truncal weight gain, supraclavicular and dorsocervical fat pads (the so-called moon face and buffalo hump), and relatively thin arms and legs from proximal muscle wasting., New or rapidly worsening violaceous abdominal, axillary, and thigh striae more than 1 cm wide — a highly specific sign reflecting collagen loss in the dermis., Easy bruising after minor trauma, thin atrophic skin that tears with adhesive removal, and poor wound healing., Hypertension with diastolic predominance, frequently resistant to standard antihypertensives., New or markedly worsening type 2 diabetes or impaired glucose tolerance from cortisol-driven gluconeogenesis and insulin resistance., Proximal muscle weakness — difficulty rising from a chair, climbing stairs, or lifting arms above the head — that often precedes other features by months., Hirsutism, acne, oligomenorrhoea or amenorrhoea, and androgenic alopecia in women, particularly in adrenal carcinoma where androgen excess is prominent..
Diagnosis proceeds in three steps: confirm hypercortisolism, determine whether it is ACTH-dependent or independent, and localize the source. The first step is recognition — clinicians should screen any patient with multiple features, particularly violaceous striae, proximal myopathy, easy bruising, supraclavicular fat pads, or resistant hypertension and diabetes appearing together. Screening tests recommended by the Endocrine Society are: 24-hour urinary free cortisol (collected over 2-3 separate days), late-night salivary cortisol (collected at 23:00 on two separate evenings; ideally a normal cortisol nadir is below 4 nmol/L or 1.5 ng/mL), and the overnight 1 mg dexamethasone suppression test (suppression of plasma cortisol to under 50 nmol/L or 1.8 µg/dL excludes Cushing's). Two positive screening tests confirm hypercortisolism. Once hypercortisolism is confirmed, plasma ACTH separates ACTH-dependent (ACTH >15 pg/mL) from ACTH-independent (ACTH <5 pg/mL) disease. In ACTH-dependent cases, MRI of the pituitary, high-dose dexamethasone suppression, and inferior petrosal sinus sampling (IPSS) distinguish Cushing's disease from ectopic ACTH syndrome — IPSS achieves over 95% accuracy in experienced centres. CRH stimulation and desmopressin testing are sometimes used. In ACTH-independent disease, CT or MRI of the adrenals localizes the lesion. For ectopic disease, 68Ga-DOTATATE PET-CT, octreoscan, and chest-abdomen CT search for occult neuroendocrine tumors. Pseudo-Cushing states require dexamethasone-CRH testing or repeated late-night salivary cortisol once the suspected trigger (alcohol, depression, severe stress) is controlled.
Outlook is excellent with timely diagnosis and effective treatment, and dismal without it. Untreated endogenous Cushing's carries 5-year mortality of 30-50%, driven by cardiovascular events, thromboembolism, opportunistic infection, and metabolic complications. With surgical or medical control of cortisol, mortality falls and approaches that of the general population, although some excess cardiovascular risk persists for years. Pituitary surgery cures 65-90% of microadenomas and 50-70% of macroadenomas at first operation; recurrence develops in 10-25% over a decade and requires lifelong surveillance with late-night salivary cortisol and 24-hour urinary free cortisol. Adrenal adenoma is cured by laparoscopic adrenalectomy in over 95%. Adrenocortical carcinoma has a much poorer outlook, with 5-year overall survival of 40-55% for localized resectable disease and under 20% for metastatic disease. Reversal of physical features after successful treatment is substantial — striae fade and muscle bulk returns within 6-18 months — but bone loss recovers slowly and cognitive and mood symptoms may take 1-3 years to improve. Up to 50% of patients have persistent quality-of-life impairment after biochemical cure, justifying long-term multidisciplinary follow-up.
Cushing's diagnosis and management are highly subspecialty-dependent. An endocrinologist with experience in pituitary and adrenal disease coordinates testing, interprets discordant results, and selects between medical and surgical options. Pituitary or adrenal surgery should be performed by high-volume surgeons because outcomes correlate strongly with operative volume.
Find specialists →Weeks 1-4: cortisol control after surgery or with osilodrostat/metyrapone; adrenal insufficiency requires hydrocortisone cover. Months 1-6: blood pressure, glucose, and electrolytes normalize; muscle strength begins to return. Months 6-12: weight redistributes from central to peripheral; striae fade from violaceous to pale; menstrual cycles resume. Years 1-3: bone density recovers slowly; cognitive and mood symptoms improve. HPA axis recovers in roughly 70% of patients by 24 months after surgical cure.
Resistance training under physiotherapy supervision (twice weekly) is the most effective intervention against proximal myopathy. Low-impact aerobic activity (walking, swimming) protects against deconditioning. Avoid high-impact loading during severe osteoporosis; falls prevention is essential.
Choose an endocrinologist affiliated with a designated pituitary or neuroendocrine centre, ideally with access to inferior petrosal sinus sampling, dynamic pituitary MRI, and the full range of medical therapies. For pituitary surgery, look for a neurosurgeon performing at least 50 transsphenoidal cases per year and reporting cure rates with hormone-specific follow-up data.
Medically reviewed by AIHealz Medical Editorial Board · May 13, 2026
Ranked by patient outcomes and specialized experience.
Verifying top specialists in Israel.
Apply as specialist →Specialists who treat Cushing's Syndrome. Get expert guidance and personalized care.